Effect of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) on Atrial Fibrillation Recurrence Rate in Patients with Type 2 Diabetes Mellitus: A Mid-Term Follow-up

Document Type : Original Article

Authors

Cardiology Department, Faculty of Medicine, Zagazig University, Egypt

Abstract

Background: Atrial Fibrillation (AF) deteriorates the prognosis of Diabetes mellitus (DM), and DM is a significant risk factor for the occurrence of AF. Because of its cardioprotective and antiarrhythmic properties, SGLT2 may lower the risk of AF in DM patients. Therefore, our goal was to assess how much SGLT2is reduced the occurrence of paroxysmal AF in patients with type 2 diabetes.

Methods: This cohort comparative study was conducted at the Cardiology Department, Zagazig University hospitals on 400 patients who were divided into two equal groups: intervention group: SGLT2 inhibitor group; included 200 patients and control group: Placebo group; included 200 patients.

Results: Incidence of AF (19.5%) in SGLT2 inhibitor group was significantly lower than incidence of AF (29%) in Placebo group, with (RR: 0.757; 95% CI: 0.581-0.986; P =0.027) and relative risk reduction (RRR) 40.6% of AF attack in SGLT2 inhibitor group.

Conclusion: In individuals with type 2 diabetes, SGLT2 inhibitors are generally linked to a decreased incidence of incident AF and have no discernible effect on stroke risk; nevertheless, these results should be interpreted cautiously until more precisely planned trials are available. SGLT2 lowers the risk of cardiovascular death and morbidity in people with Type 2 diabetes. Because of its cardioprotective and antiarrhythmic properties, SGLT2 may lower the risk of AF in DM patients. Patients with type 2 diabetes may experience fewer episodes of paroxysmal AF thanks to SGLT2's cardioprotective and antiarrhythmic actions.

Keywords

Main Subjects

Zagazig University Medical Journal
Volume 31, Issue 8
August 2025
Pages 4281-4292

Files

Share

How to cite

Statistics